// App-Quantinova.ai

591 : Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Researchers

Presenter

  • Sinead Toomey

Principal Investigators

  • Joanna Fay

  • Malgorzata Milewska

  • Ausra Teiserkiene

  • Elaine Kay

  • Darran O'Connor

  • Leonie S Young

  • Norma O'Donovan

  • William Grogan

  • Oscar S. Breathnach

  • Janice Maria Walshe

  • M. John Kennedy

  • Arnold D. Hill

  • Colm Power

  • Deirdre Duke

  • Niamh Hambly

  • William M. Gallagher

  • John Crown

  • Bryan Hennessy

Medical Centers

  • Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland

  • Medical Oncology, Royal College of Surgeons in Ireland, Dublin, Ireland

  • Medical Oncology, Royal College of Surgeons in Ireland, Dublin, Ireland

  • Royal College of Surgeons in Ireland, Dublin, Ireland

  • ICORG, Dublin, Ireland

  • Royal College of Surgeons in Ireland, Centre for Systems Medicine, Department of Pathology, Beaumont Hospital, Dublin, Ireland

  • University College Dublin, Dublin 4, Ireland

  • Endocrine Oncology Research Group, Royal College of Surgeons in Ireland, Dublin, Ireland

  • Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland

  • St Vincent's University Hospital, Dublin, Ireland

  • Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland

  • LRCP & SI MB BCh NUI, Beaumont Hospital, Dublin, Ireland

  • Irish Cooperative Oncology Research Group, Dublin, Ireland

  • Royal College of Surgeons in Ireland, Centre for Systems Medicine, Department of Pathology, Beaumont Hospital, Dublin, Ireland

Locations

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Epidermal growth factor receptor

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Carboplatin

  • Trastuzumab

  • Docetaxel

  • Lapatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved